A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

BACKGROUND: The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma. METHODS: Galunisertib (300 mg/day) was given orally 14 days on/14 days off (intermittent dosing). Lom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Brandes, Alba A., Carpentier, Antoine F., Kesari, Santosh, Sepulveda-Sanchez, Juan M., Wheeler, Helen R., Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P., Capper, David, Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C., Desaiah, Durisala, Lahn, Michael M., Wick, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933481/
https://ncbi.nlm.nih.gov/pubmed/26902851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados